Rhythm Pharmaceuticals (RYTM) Tops Q4 EPS by 9c

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q4 EPS of ($0.73), $0.09 better than the analyst estimate of ($0.82). Revenue for the quarter came in at $57.3 million versus the consensus estimate of $55.24 million.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.

You May Also Be Interested In

• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
• JPMorgan Starts Multi Commodity Exchange of India Ltd (MCX:IN) at Underweight
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings